Trial · NCT04305327
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Psoriasis Area and Severity Index (PASI) 75 Response, Assessed at Week 12. | Baseline to Week 12 | Participants who completed at Week 12 are included in the overall number of participants analysed. Dataset from the full analysis set (FAS) which includes all randomized participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Static Physician's Global Assessment (sPGA) Score of 0 or 1, Assessed at Week 12. | Week 12 | Due to early termination, data was not collected | ||
| SECONDARY | sPGA Score of 0, Assessed at Week 12. | Week 12 | Due to early termination, data was not collected | ||
| SECONDARY | PASI 90 Response, Assessed at Week 12. | Baseline to Week 12 | Participants who completed at Week 12 are included in the overall number of participants analysed. Dataset from the FAS which includes all randomized participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | PASI 100 Response, Assessed at Week 12. | Baseline to Week 12 | Participants who completed at Week 12 are included in the overall number of participants analysed. Dataset from the FAS which includes all randomized participants. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Children's Dermatology Life Quality Index (CDLQI) Total Score of 0 or 1, Assessed at Week 12. | Week 12 | Due to early termination, data was not collected | ||
| SECONDARY | Family Dermatology Life Quality Index (FDLQI) Total Score of 0 or 1, Assessed at Week 12. | Week 12 | Due to early termination, data was not collected | ||
| SECONDARY | Overall Number of Adverse Events (AEs) | Up to approximately 5 months | Dataset from the safety analysis set (SAS) which includes all participants who received at least 1 dose of IMP. | Adverse events | NUMBER |
| SECONDARY | Presence of Anti-drug Antibodies, Assessed at Weeks 4, 16, and 52. | Week 4, Week 16, and Week 52 | Due to early termination, data was not collected | ||
| SECONDARY | Serum Concentration of Interleukin-17, Assessed at Weeks 8, 12, and 52. | Week 8, Week 12, and Week 52 | Due to early termination, data was not collected | ||
| SECONDARY | Blood Levels of T-cell Subsets (CD4+ and CD8+), Assessed at Weeks 8, 12, and 52. | Week 8, Week 12, and Week 52 | Due to early termination, data was not collected | ||
| SECONDARY | Serum Concentrations of Brodalumab, Assessed at Weeks 4, 8, 10, 12, 16, 22, and 52. | Week 4, Week 8, Week 10, Week 12, Week 16, Week 22, and Week 52 | Due to early termination, data was not collected | ||
| SECONDARY | Anti-tetanus Toxoid Antibodies ≥0.1 IU/mL, Assessed at Week 12. | Week 12 | Due to early termination, data was not collected |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04305327/outcomes